Andrew Jensen

Andrew Irving Jensen is the Chief Financial Officer of Kearny Venture Partners, a San Francisco healthcare venture-capital firm. Public profiles list him as Director of Finance/CFO at Kearny beginning May or June 2008, and The Org states that he joined Kearny as CFO in 2008.

Jensen is also listed as a board member of NewBridge Pharmaceuticals, a Dubai-based pharmaceutical and medical-device company. His LinkedIn profile identifies him with NewBridge Pharmaceuticals and UC Berkeley, and The Org lists him on NewBridge’s board.

Before Kearny, Jensen held senior finance roles across venture capital, private equity, and real-estate private equity. The Org states that he began his career in audit with Andersen, then held senior financial positions with Sanderling Ventures, Gryphon Investors, IIX, and Clairvue Capital Partners. ContactOut and VC DATALAB additionally list prior roles including Director of Finance at Sanderling Ventures, Senior Controller at Gryphon Investors, CFO at Liquid Realty Partners, and Finance and Accounting Advisor at Clairvue Capital Partners.

Jensen is a UC Berkeley graduate. VC DATALAB describes him as a California CPA with a BA in Finance and Accounting with honors from the University of California, Berkeley.

• Kearny Venture Partners is not an angel-investor platform in the public sources reviewed; it is a healthcare-focused venture-capital firm.
• The firm says it is “exclusively focused on emerging healthcare products” and aims to help companies “transform medicine.”
• Kearny focuses on medical devices and drugs, including small molecules and biopharmaceuticals.
• The firm invests across company stages, including founding/formation rounds, seed, early, expansion, growth, and later-stage financings.
• Public database profiles describe Kearny as investing in U.S. healthcare companies and participating in early-stage transactions.
• Kearny’s stated rationale centers on large unmet medical needs, safe and effective products, advances in disease biology, and novel therapies displacing incumbent products.
• Jensen appears publicly as CFO and finance/board operator rather than as a named deal partner; founder outreach should assume he may be involved in finance, fund administration, diligence, or portfolio governance rather than first-pass sector sponsorship.